A potent oral multi-kinase inhibitor becoming studied in multiple tumor types.

Bayer is focused on discovering fresh cancer-fighting therapies, stated Kemal Malik, MD, Chief Medical Mind and Officer of Global Advancement at Bayer HealthCare. We are motivated by these Stage I and II data becoming presented on BAY 73-4506. These data can help additional determine our next methods as we progress with a thorough Phase III clinical advancement program in a variety of tumor types because of this new drug candidate. Preliminary data from the Stage II, open-label research in renal cell carcinoma demonstrated a 27 % partial response rate based on the Response Evaluation Requirements in Solid Tumors and an illness control price of 79 %.‘But the costs being imposed by clinics focusing on this field are putting it out of reach for many. With the starting of the clinic, and future locations, we are making medical marijuana even more accessible to those sufferers considering it as a treatment choice.’ Related StoriesNew review finds scant scientific evidence supporting use of cannabinoids in rheumatic diseasesEndocannabinoids make a difference development of baby's pancreasDigiPath Labs, Romer Labs to validate kit-based assays for food-borne pathogen, mycotoxin assessment for cannabisCanadian Cannabis Clinics has also partnered with Canada's leading medical marijuana counselling and resource service, CanvasRx, to educate and inform individuals about medical cannabis options.